423 related articles for article (PubMed ID: 22275381)
1. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
[TBL] [Abstract][Full Text] [Related]
2. The TP53 tumor suppressor and autophagy in malignant lymphoma.
Xu-Monette ZY; Young KH
Autophagy; 2012 May; 8(5):842-5. PubMed ID: 22498492
[TBL] [Abstract][Full Text] [Related]
3. TP53 dysfunction in diffuse large B-cell lymphoma.
Lu TX; Young KH; Xu W; Li JY
Crit Rev Oncol Hematol; 2016 Jan; 97():47-55. PubMed ID: 26315382
[TBL] [Abstract][Full Text] [Related]
4. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
5. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target.
Cheung KJ; Horsman DE; Gascoyne RD
Br J Haematol; 2009 Aug; 146(3):257-69. PubMed ID: 19500100
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.
Timmerman DM; Remmers TL; Hillenius S; Looijenga LHJ
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065345
[TBL] [Abstract][Full Text] [Related]
8. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
9. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
10. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
12. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.
Tessoulin B; Eveillard M; Lok A; Chiron D; Moreau P; Amiot M; Moreau-Aubry A; Le Gouill S; Pellat-Deceunynck C
Blood Rev; 2017 Jul; 31(4):251-259. PubMed ID: 28284458
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome.
Speciale A; Monti P; Fronza G; Izzotti A; Menichini P
Microrna; 2020; 9(5):322-335. PubMed ID: 33297928
[TBL] [Abstract][Full Text] [Related]
14. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
15. Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling.
Sharma S; Munger K
mBio; 2020 Jun; 11(3):. PubMed ID: 32546626
[TBL] [Abstract][Full Text] [Related]
16. Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.
Blandino G; Valenti F; Sacconi A; Di Agostino S
Semin Cell Dev Biol; 2020 Feb; 98():105-117. PubMed ID: 31112799
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network.
Samuel N; Wilson G; Id Said B; Pan A; Deblois G; Fischer NW; Alexandrova R; Casallo G; Paton T; Lupien M; Gariepy J; Merico D; Hudson TJ; Malkin D
Oncotarget; 2016 Aug; 7(31):49611-49622. PubMed ID: 27391063
[TBL] [Abstract][Full Text] [Related]
18. Modeling the Etiology of p53-mutated Cancer Cells.
Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
20. Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
Silva JL; Lima CGS; Rangel LP; Ferretti GDS; Pauli FP; Ribeiro RCB; da Silva TB; da Silva FC; Ferreira VF
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
